Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $475,000.

  • Ironwood Pharmaceuticals' Depreciation & Amortization (CF) fell 6.31% to $475,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 6.48%. This contributed to the annual value of $1.2 million for FY2024, which is negligibly% changed negligibly from last year.
  • Ironwood Pharmaceuticals' Depreciation & Amortization (CF) amounted to $475,000 in Q3 2025, which was up 1.71% from $467,000 recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $513,000 during Q1 2024, and its lowest value of $270,000 during Q2 2023.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Depreciation & Amortization (CF) value was $485,000 (recorded in 2024), while the average stood at $455,182.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first tumbled by 80.34% in 2021, then surged by 87.41% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $359,000 in 2021, then dropped by 5.29% to $340,000 in 2022, then skyrocketed by 50.59% to $512,000 in 2023, then declined by 5.27% to $485,000 in 2024, then decreased by 6.31% to $475,000 in 2025.
  • Its last three reported values are $475,000 in Q3 2025, $467,000 for Q2 2025, and $479,000 during Q1 2025.